Myriad Genetics (MYD) AI Stock Analysis
Myriad Genetics
(XETRA:MYD)
No summary available
Myriad Genetics (MYD) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 607.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,220
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 0.21
- Revenue Growth
- -9.69%
- EPS Growth
- 73.04%
- Country
- Germany
- Employees
- 2,700
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Myriad Genetics Business Overview & Revenue Model
Company Description
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Myriad Genetics Earnings Call Summary
The call emphasized meaningful progress in core growth engines (double-digit hereditary cancer growth, robust GeneSight performance, solid gross margins and a deep product pipeline) and management reaffirmed full-year guidance and positive adjusted EBITDA expectations. Near-term pressures include a Q1 adjusted EBITDA loss, higher operating expense due to accelerated commercial hiring, and a notable prenatal revenue decline. Management is investing to drive back-half acceleration but execution (sales ramp, MRD adoption, payer reimbursement) will determine pace of recovery. On balance, the positives around market share gains, product launches and revenue guidance outweigh the short-term profitability and prenatal headwinds.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed full‑year 2026 guidance of $860–$880 million revenue, adjusted gross margin of 68–69% and adjusted EBITDA of $37–$49 million, while expecting sequential revenue growth in the low single digits in Q2 that accelerates through the back half (H2 stronger than H1). Q1 results were revenue $200.4M (within guidance) with 385k test results, gross margin ~68.7–69%, an adjusted EBITDA loss of roughly $4.5–$5.0M and adjusted EPS loss of $0.09; average revenue per test improved ~2% YoY. Operational highlights underpinning the guide included Cancer Care Continuum revenue of $120.2M (+4% YoY) with hereditary testing volume +14% YoY (affected +10%, unaffected +16%), GeneSight revenue $38.3M (+24% YoY) on +7% volume and >39,000 ordering clinicians, prenatal revenue $41.9M (‑15% YoY) and Prolaris mid‑single‑digit growth. Management also cited $199M in available capital, a planned $35M investment in commercial capabilities, hiring of over 100 account executives, and timing for key launches (Prolaris+AI in June, FirstGene commercial in H2’26, broader Precise MRD expansion in Q3 and full MRD commercialization in Q1’27).
Myriad Genetics Risk Analysis
Myriad Genetics disclosed 52 risk factors in its most recent earnings report. Myriad Genetics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksMyriad Genetics Peers Comparison
Overall Rating
VCYT78Outperform
CSTL70Outperform
NTRA67Neutral
FLGT50Neutral
WGS48.2Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VCYT | 78Outperform | $4.02B | 34.73 | 8.64% | ― | 17.28% | 323.64% |
| CSTL | 70Outperform | $1.14B | -56.34 | -4.15% | ― | 3.18% | -100.37% |
| NTRA | 67Neutral | $59.72B | -304.63 | -11.73% | ― | 37.82% | 28.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FLGT | 50Neutral | $567.37M | -7.31 | -7.87% | ― | 6.83% | -69.59% |
| WGS | 48Neutral | $2.06B | -18.97 | -38.72% | ― | 25.42% | -10900.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:MYD | Myriad Genetics | 5.71 | -1.14 | -16.64% | |
| VCYT | Veracyte Inc | 50.01 | 13.56 | 37.20% | |
| NTRA | Natera Inc. | 414.30 | 216.07 | 109.00% | |
| FLGT | Fulgent Genetics | 20.62 | -2.49 | -10.77% | |
| CSTL | Castle Biosciences | 37.16 | 11.17 | 42.98% | |
| WGS | Genedx Holdings Corp. | 69.06 | -69.24 | -50.07% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.